Hemostasis is an active process regulating the formation and dissolution of fibrin clot to preserve vascular integrity. The different phases of hemostasis are coordinated so that effective clotting occurs only at the site of vascular injury while maintaining blood flow in other parts of the circulation. Procoagulant processes culminate in thrombin generation and fibrin clot formation to protect...

Despite the criticisms of substrate variability, the euglobulin lysis time remains a most useful assay of plasma plasminogen activator. It is simple to execute and correlates well with the radioactive clot assay (Sawyer, Fletcher, Alkjaersig, and Sherry, 1960), dilute blood clot lysis time (Fearnley, Balmforth, and Feamley, 1957), and fibrin plate method (Kekwick and Mackay, 1954). It continues...

T HE FINAL STEPS OF THE CLOTTING PROCESS, in which fibrinogen (Factor I) is transformed to fibrin through the action of thrombin, is customanily described as taking place in three stages. Initially, thrombin, a proteolytic enzyme of high substrate specificity, cleaves four arginyl-glycine bonds in each fibrinogen molecule, so that two pairs of peptide fragments are released. During the second s...

BACKGROUND Periodontal regeneration is dependent on the uninterrupted adhesion, maturation and absorption of fibrin clots to a periodontally compromised root surface. The modification of the root surface with different agents has been used for better fibrin clot formation and blood cell attachment. It is known that Er:YAG laser application on dentin removes the smear layer succesfully. AIM Th...

Abstract Background Colloid fluids supplemented with adequate combinations of coagulation factor concentrates the capability to restore could be a desirable future treatment component in massive transfusion. Methods Starting from and blood cell-free albumin solution we added Prothrombin Complex Concentrate, Fibrinogen Concentrate Factor XIII different concentrations analyze their properties thr...

Plasminogen activator inhibitor-1 (PAI-1) is the major specific inhibitor of tissue-type plasminogen activator (tPA) which mediates fibrin clot lysis through activation of plasminogen. Wild-type-PAI-1 (wPAI-1) is rapidly converted to the latent form (half-life of approximately 2 h) and loses its ability to inhibit tPA. We developed a very long half-life PAI-1 (VLHL PAI-1), a recombinant protein...

OBJECTIVE This study was performed to evaluate the influences of phospholipids and recombinant factor VIIa (rFVIIa) on thrombin generation and clot formation in "acquired" hemophilia B. METHODS AND RESULTS A synthetic mixture corresponding to hemophilia A (SHA) and "acquired" hemophilia B blood (AHBB) manufactured in vitro by an anti-FIX antibody were used in this study. With 10 pmol/L tissue...

BACKGROUND Stroke is the second largest cause of death worldwide. Hypercoagulability is a key feature in ischaemic stroke due to the development of an abnormally dense clot structure but techniques assessing the mechanics and quality of clot microstructure have limited clinical use. We have previously validated a new haemorheological technique using three parameters to reflect clot microstructu...

T HE RELATIONSHIP of platelets and fibrin has interested investigators since the early descriptions of human blood clots.’4 Many studies showed an intimate platelet-fibrin association which indicated that platelets served as centers of clot formation, and as the main support of the fibrin meshwork.5’#{176} Other reports, however, described the relationship to be accidental; that is, platelets a...